IL114415A0 - Anti-HIV triple therapeutic combination - Google Patents

Anti-HIV triple therapeutic combination

Info

Publication number
IL114415A0
IL114415A0 IL11441595A IL11441595A IL114415A0 IL 114415 A0 IL114415 A0 IL 114415A0 IL 11441595 A IL11441595 A IL 11441595A IL 11441595 A IL11441595 A IL 11441595A IL 114415 A0 IL114415 A0 IL 114415A0
Authority
IL
Israel
Prior art keywords
hiv
therapeutic combination
triple
triple therapeutic
combination
Prior art date
Application number
IL11441595A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL114415A0 publication Critical patent/IL114415A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL11441595A 1994-07-01 1995-06-30 Anti-HIV triple therapeutic combination IL114415A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94201897 1994-07-01

Publications (1)

Publication Number Publication Date
IL114415A0 true IL114415A0 (en) 1995-10-31

Family

ID=8217000

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11441595A IL114415A0 (en) 1994-07-01 1995-06-30 Anti-HIV triple therapeutic combination

Country Status (25)

Country Link
EP (1) EP0768881B1 (et)
JP (1) JP2945481B2 (et)
KR (1) KR100218495B1 (et)
CN (1) CN1091599C (et)
AP (1) AP9600896A0 (et)
AT (1) ATE218867T1 (et)
AU (1) AU693911B2 (et)
BG (1) BG101175A (et)
BR (1) BR9508201A (et)
CA (1) CA2193489A1 (et)
CZ (1) CZ375596A3 (et)
DE (1) DE69527066T2 (et)
EE (1) EE9600180A (et)
FI (1) FI965292A0 (et)
HU (1) HUT77720A (et)
IL (1) IL114415A0 (et)
MX (1) MX9700044A (et)
MY (1) MY130597A (et)
NO (1) NO965556L (et)
OA (1) OA10341A (et)
PL (1) PL317891A1 (et)
SK (1) SK168196A3 (et)
TW (1) TW401303B (et)
WO (1) WO1996001110A2 (et)
ZA (1) ZA955471B (et)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008539A1 (en) * 1996-08-26 1998-03-05 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
EP0872233A1 (en) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretroviral compositions with improved bioavailability
JP4919566B2 (ja) 1999-09-24 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗ウイルス組成物
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EP2435052B1 (en) 2009-05-27 2015-07-15 Hetero Research Foundation Solid oral dosage forms of lamivudine with isomalt
WO2018119371A1 (en) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0513917T4 (da) * 1991-05-16 2001-06-25 Glaxo Group Ltd Antivirale kombinationer indeholdende nukleosidanaloger

Also Published As

Publication number Publication date
ZA955471B (en) 1996-12-30
BG101175A (en) 1997-08-29
KR100218495B1 (en) 1999-09-01
EP0768881A2 (en) 1997-04-23
TW401303B (en) 2000-08-11
AU693911B2 (en) 1998-07-09
HUT77720A (hu) 1998-07-28
FI965292A (fi) 1996-12-31
MY130597A (en) 2007-07-31
EP0768881B1 (en) 2002-06-12
JP2945481B2 (ja) 1999-09-06
JPH09507858A (ja) 1997-08-12
SK168196A3 (en) 1997-05-07
EE9600180A (et) 1997-06-16
ATE218867T1 (de) 2002-06-15
AP9600896A0 (en) 1997-01-31
CN1091599C (zh) 2002-10-02
NO965556D0 (no) 1996-12-23
OA10341A (en) 1997-10-07
CN1151697A (zh) 1997-06-11
AU2924895A (en) 1996-01-25
DE69527066D1 (de) 2002-07-18
WO1996001110A3 (en) 1996-02-22
CA2193489A1 (en) 1996-01-18
WO1996001110A2 (en) 1996-01-18
MX9700044A (es) 1997-04-30
CZ375596A3 (en) 1997-04-16
PL317891A1 (en) 1997-04-28
HU9603627D0 (en) 1997-02-28
BR9508201A (pt) 1997-11-11
FI965292A0 (fi) 1996-12-31
DE69527066T2 (de) 2003-02-13
NO965556L (no) 1996-12-23

Similar Documents

Publication Publication Date Title
GB9419536D0 (en) Medicaments
GB9406573D0 (en) Medicaments
ZA9533B (en) Pentolifylline therapy
GB9420784D0 (en) Medicaments
IL114415A0 (en) Anti-HIV triple therapeutic combination
AP9600897A0 (en) anti-HIV triple combination
AU2547895A (en) Therapeutic phenoxyalkylheterocycles
GB9418530D0 (en) Medicaments
GB9401879D0 (en) Therapeutic agents
EP0830862A4 (en) ANTI HIV MEDICINAL PRODUCTS
GB9421133D0 (en) Medicaments
GB9411052D0 (en) Medicaments
GB9416365D0 (en) Medicaments
GB9424013D0 (en) Medicaments
EP0790829A4 (en) DRUG
GB9420340D0 (en) Therapeutic improvement
GB9404379D0 (en) Therapeutic improvement
GB9416158D0 (en) Medicaments
GB9425055D0 (en) Medicaments
GB9416645D0 (en) Medicaments
GB9416126D0 (en) Medicaments
GB9414896D0 (en) Medicaments
GB9414191D0 (en) Medicaments
GB9420699D0 (en) Medicaments
GB9420704D0 (en) Medicaments